Browsing by Publisher "K FAISAL SPEC HOSP RES CENTRE"

Now showing 1 - 7 of 7
  • No Thumbnail Available
    Item
    Cryptosporidium spp. during chemotherapy: a cross-sectional study of 94 patients with malignant solid tumor
    (K FAISAL SPEC HOSP RES CENTRE) Karabey, M; Can, H; Öner, TÖ; Döskaya, M; Alak, SE; Döskaya, AD; Karakavuk, M; Köseoglu, AE; Ün, C; Gürüz, AY; Alacacioglu, A; Pektas, B; Gül, A; Kaya, S; Gokmen, AA
    BACKGROUND: Cryptosporidium spp. is a protozoan parasite that infects many vertebrate animals, including humans. Since Cryptosporidium spp. can cause chronic life-threatening diarrhea and severe malabsorption in immunocompromised patients, we investigated the prevalence of this parasite among patients undergoing chemotherapy for malignant solid tumors. OBJECTIVE: Investigate the prevalence of Cryptosporidium spp. in stool samples. DESIGN: Cross-sectional. SETTING: Tertiary care. PATIENTS AND METHODS: Stool samples were collected from adult patients with malignant solid tumors receiving chemotherapy and diarrhea. Cryptosporidium spp. prevalence was determined using Ziehl-Neelsen staining, ELISA, and real-time PCR targeting of the COWP gene. MAIN OUTCOME MEASURE: The prevalence of Cryptosporidium spp. in patients undergoing chemotherapy for malignant solid tumors. SAMPLE SIZE: 94 RESULTS: The prevalence was 2.1% (2/94), 5.3% (5/94), and 5.3% (5/94) as detected by Ziehl-Neelsen staining, real-time PCR and ELISA, respectively. The prevalence reached 8.5% (8/94) using all results obtained from the three methods. Among eight positive stool samples, four were positive by at least two different methods (Ziehl-Neelsen staining-ELISA or ELISA-real-time PCR) whereas the remaining four were positive by either ELISA or real-time PCR. CONCLUSION: These findings show the risk of cryptosporidiosis in cancer patients and the necessity to use at least two diagnostic methods during the diagnosis of cryptosporidiosis to reach more accurate and trustworthy results. LIMITATIONS: Further studies with a larger sample size are recommended. CONFLICT OF INTEREST: None.
  • No Thumbnail Available
    Item
    In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium tuberculosis
    (K FAISAL SPEC HOSP RES CENTRE) Akcali, S; Surucuoglu, S; Cicek, C; Ozbakkaloglu, B
    BACKGROUND:The increasing incidence of drug-resistant Mycobacterium tuberculosis necessitates therapeutic alternatives. The fluoroquinolones fulfill most of the criteria for an ideal class of antimycobacterial drugs. The aim of the present study was to determine to in vitro activities of ciprofloxacin, ofloxacin, and levofloxacin against M. tuberculosis strains. METHODS: Susceptibility to four antituberculous drugs used in first-line treatment of tuberculosis was tested in 100 strains isolated from clinical samples. Nineteen strains (19%) were resistant to at least one of the four antituberculous drugs and 13 were multidrug resistant. The in vitro antimycobacterial activity of ciprofloxacin, ofloxacin, and levofloxacin was then determined against 100 M. tuberculosis strains using standard agar proportion dilution method. RESULTS: Ciprofloxacin, ofloxacin, and levofloxacin were active against all tested strains of M. tuberculosis in vitro. CONCLUSIONS: Ciprofloxacin, ofloxacin, and levofloxacin have relatively potent in vitro activity against M. tuberculosis. Further in vivo studies are needed to determine the role of these compounds in the treatment of tuberculosis, but use should be limited to special circumstances rather than first-line treatment.
  • No Thumbnail Available
    Item
    Cardiovascular findings in patients with psoriasis
    (K FAISAL SPEC HOSP RES CENTRE) Öztürkcan, S; Ermertcan, AT; Sekuri, C; Kylyççyoòlu, B
  • No Thumbnail Available
    Item
    Drug-resistant pulmonary tuberculosis in western Turkey: prevalence, clinical characteristics and treatment outcome
    (K FAISAL SPEC HOSP RES CENTRE) Surucuoglu, S; Ozkutuk, N; Celik, P; Gazi, H; Dinc, G; Kurutepe, S; Koroglu, G; Havlucu, Y; Tuncay, G
    BACKGROUND: Although high antituberculosis (anti-TB) drug resistance rates have been reported in Turkey, the clinical characteristics and implications for the outcome of anti-TB treatment have not been fully investigated. We determined the prevalence of anti-TB drug resistance and examined demographic data, clinical characteristics and treatment outcome in relation to patterns of resistance. METHODS: From the TB case registry of a university hospital and the two largest dispensaries in Manisa city, we identified all pulmonary TB cases with a culture-proven definitive diagnosis and antimicrobial susceptibility results for a 7-year period. We collected and analyzed demographic and clinical data and information on treatment outcome for those cases in relationship to anti-TB drug resistance. RESULTS: Of 355 M. tuberculosis strains, 71.5% were susceptible to streptomycin, isoniazid, rifampicin and ethambutol. Any drug resistance and multi-drug resistance (MDR) rates were 21.1% and 7.3% and were higher in males (53% and 9%, respectively) than in females (22% and 1%, respectively). Drug resistance was significantly higher in old cases (acquired drug resistance) vs new cases (primary drug resistance), and was associated with treatment failure (P<0.001). The prevalence of MDR was significantly higher in the old cases (22.4%) than in the new cases (4.4%) (P<0.001). Symptoms, radiographic findings, associated diseases, and sputum smear positivity were unrelated to the development of resistance. The prevalence of any drug resistance and MDR was significantly higher in those with treatment failure than in patients with treatment success. CONCLUSION: High resistance rates, particularly for acquired MDR, indicate a need for improvement in the TB control programme in our region.
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    A 46-year-old male with an ulcerated linear lesion on his neck
    (K FAISAL SPEC HOSP RES CENTRE) Yoleri, L; Ozden, S; Kandiloglu, A
  • No Thumbnail Available
    Item
    Lung involvement in inflammatory bowel diseases
    (K FAISAL SPEC HOSP RES CENTRE) Sarioglu, N; Türkel, N; Sakar, A; Çelik, P; Saruç, M; Demir, MA; Göktan, C; Kirmaz, C; Yüceyar, H; Yorgancioglu, A